by GMFH Editing Team
Significant strides have been made in our comprehension of the role of the gut microbiome in health and disease throughout the year 2022. We invite you to take a closer look at the "2022 Year at a Glance" report and learn about the groundbreaking discoveries made.
by GMFH Editing Team
Fecal microbiota transplantation is being studied in the context of metabolic health, beyond its use for recurrent Clostridioides difficile infection. A new proof-of-principle study reveals that supplementing low-fermentable fiber following fecal microbiota transplantation may improve insulin sensitivity in individuals with severe obesity.
by Andreu Prados
The microbiota of infants born by caesarean section resembles that of maternal oral cavity and skin, whereas that of vaginally born infants resembles that of the maternal gut microbiome. A new proof-of-concept study shows that the gut microbiota of C-section-born infants can be restored after delivery via orally administered maternal fecal microbiota transplantation.
by Andreu Prados
An altered balance of the community of microbes that reside in our body, especially within the gut, has been linked to a wide range of intestinal and extraintestinal diseases. What evidence-based strategies are currently available for modulating the gut microbiota?
by Stéphane Schneider
The benefits of fecal microbiota transplantation in treating Clostridioides difficile infection are well documented. Despite this, a new study concerns the transfer of extended-spectrum beta-lactamase-producing Escherichia coli in two immunocompromised adults.
by GMFH Editing Team
GMFH continue to cover the important progress made in our knowledge of the gut microbiota's impact on wellbeing and disease.
by Paul Enck
this is the first study that has simultaneously studied the impact of FMT on IBS symptoms and changes in the gut microbiota's composition.
The ultimate goal would be to create an "artificial stool", a consortium of commensal bacteria fermented and harvested in vitro,
by Andreu Prados
This study provides an in-depth picture of the contribution of the interactions between gut metagenome and host molecular phenome data as a means of identifying subgroups of patients with different degrees of hepatic steatosis.
A scientific committee chaired has taken care to put together a program that covers the most relevant issues in the field today.
